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Phospholipases C (PLC) 1 and 2 are a class of highly homo-
logous enzymes modulating a variety of cellular pathways
through production of inositol 1,4,5-trisphosphate and diacylg-
lycerol (DAG). Our previous studies demonstrated the impor-
tance of PLC2 in osteoclast (OC) differentiation bymodulating
inositol 1,4,5-trisphosphate-mediated calcium oscillations and
the up-regulation of the transcription factor NFATc1. Surpris-
ingly, despite being expressed throughout osteoclastogenesis,
PLC1 did not compensate for PLC2 deficiency. Because both
isoforms are activated during osteoclastogenesis, it is plausible
that PLC1 modulates OC development independently of
PLC2. Here, we utilized PLC1-specific shRNAs to delete
PLC1 in OC precursors derived from wild type (WT) mice.
Differently from PLC2, we found that PLC1 shRNA signifi-
cantly suppresses OC differentiation by limiting colony-stimu-
lating factor 1 (CSF-1)-dependent proliferation and -catenin/
cyclinD1 levels. Confirming the specificity toward CSF-1
signaling, PLC1 is recruited to the CSF-1 receptor following
exposure to the cytokine. To understand how PLC1 controls
cell proliferation, we turned to its downstream effector, DAG.
Byutilizing cells lacking theDAGkinase , whichhave increased
DAG levels,wedemonstrate thatDAGmodulatesCSF-1-depen-
dent proliferation and -catenin/cyclinD1 levels in OC precur-
sors.Most importantly, the proliferation and osteoclastogenesis
defects observed in the absence of PLC1 are normalized in
PLC1/DAG kinase  double null cells. Taken together, our
study shows that PLC1 controls OC numbers via a CSF-1-de-
pendent DAG/-catenin/cyclinD1 pathway.
Phospholipase C (PLC)4 family members PLC1 and
PLC2 are critical regulators of signaling pathways down-
stream of growth factor receptors, integrins, and immune com-
plexes andmodulate a variety of signaling pathways involved in
cell differentiation, motility, and adhesion to name a few (1–3).
The main function of the PLC family is to cleave phosphati-
dylinositol 4,5-bisphosphate (PIP2) into two secondary mes-
sengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
(DAG). IP3, in turn, increases intracellular calcium levels via
binding to the IP3 receptors on the endoplasmic reticulum,
whereas DAG serves as an endogenous activator of protein
kinase C (2, 4).
Generation of knock-out animals has identified critical and
non-redundant functions of the two PLC enzymes. PLC1 is
ubiquitously expressed, whereas PLC2 is mainly expressed in
hematopoietic lineage cells (5). PLC1-deficient mice die
soon after embryonic day 8.5, and embryos show impaired vas-
culogenesis and erythropoiesis (6). Interestingly, PLC2 is
expressed in the PLC1/ embryos but is not sufficient to
prevent the early lethality (7). By contrast, global PLC2 knock-
outmice are viable but have a variety of immunological defects,
including impaired inflammatory responses in models of
arthritis or infections (8–10), developmental defects in the
lymphatic system (11), and high bone mass due to defective
osteoclastogenesis (12). Structure analysis of the two enzymes
indicates over 90% homology in the catalytic domain, which
mediates the conversion of PIP2 into IP3 and DAG, whereas
50–60% homology is observed within the SH2 and SH3 adapt-
ive motifs (2). Interestingly, however, the different phenotype
of the two null mice suggests distinct, non-overlapping specific
roles for each enzyme (5).
So far, the majority of the studies have indicated that each
PLC isoform has cell type-specific effects. For example, T cells
express both PLC1 and PLC2, but only PLC1 modulates T
cell receptor signaling and thus T cell functions (13). In B cells,
deletion of PLC2 affects B cell differentiation (14), and there
are no reports suggesting any role for PLC1 in this population.
Similar findingswere reported in dendritic cells (8), neutrophils
(9), macrophages (15), platelets (16), and osteoclasts (12) where
deletion of PLC2 impaired specific cellular functions regard-
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less of PLC1 expression. Interestingly, in platelets, enforced
expression of PLC1 in PLC2/ cells restores glycoprotein
VI-dependent aggregation and IIb3-dependent spreading
defects, suggesting that reduced PLC1 levels might be respon-
sible for the lack of compensation in the in vivo setting (16).
Whether the non-overlapping effects of PLC1 and PLC2 are
due to different levels of expression or non-redundant func-
tions remains to be established.
To delve into the specificity of PLC signaling, we turned to
the osteoclasts, which express both isoforms throughout oste-
oclast maturation. Osteoclasts are multinucleated giant cells
derived from monocyte/macrophage lineage cells, attached to
the bone surface, and responsible for bone degradation during
normal bone remodeling and during pathological bone loss
(17). The process of osteoclast differentiation requires activa-
tion of osteoclastogenic pathways through binding of RANKL
to its receptor RANK and survival and proliferative cues acti-
vated by CSF-1 and its receptor CSF-1R (17, 18). Interestingly,
both PLC1 and PLC2 are expressed and phosphorylated dur-
ing the osteoclast differentiation process (12), and it is believed
that both isoforms contribute to IP3-mediated calcium fluxes
and NFATc1 up-regulation in response to RANKL (12, 19).
However, studies from PLC2/ mice show a complete
absence of NFATc1 expression and blockade of osteoclast dif-
ferentiation despite normal expression of PLC1 (12, 20). The
current study was designed to answer two important questions:
does PLC1 play any role during osteoclast differentiation, and
why does PLC1 not compensate for the lack of PLC2 despite
the high homology? Answering these questions will aid the
design of better strategies to target the PLC pathway in path-
ological bone loss and will improve our understanding of the
specificity of PLC signaling.
Results
PLC1 deficient mice exhibit early embryonic lethality (6),
thus limiting our ability to study the effects of PLC1 deletion
in osteoclasts. To overcome this issue, we screened various
shRNA constructs targeting PLC1 but not PLC2. We identi-
fied five PLC1 shRNAs showing high knockdown efficiency
and specificity for PLC1 that did not affect PLC2 (Fig. 1A).
Next, we expressed the five shRNA constructs in primary OC
precursors via lentivirus infection and examined the effects of
PLC1 deletion on osteoclastogenesis. All five shRNA-infected
OC precursors exhibited a severe defect in osteoclast differen-
tiation (Fig. 1B), suggesting that PLC1, similarly to PLC2, is a
critical regulator of osteoclast differentiation. Interestingly,
however, shPLC1 cultures (also referred throughout the text
as PLC1-knocked down or PLC1-deficient) showed no
reduction in expression of NFATc1, c-Fos, and c-Src (Fig. 1C),
all known osteoclastogenic pathways affected by PLC2 defi-
ciency (12). This finding suggested that PLC1 governs oste-
oclast differentiation via a different mechanism than PLC2.
Interestingly, we observed that PLC1-knocked down OC
precursor cultures had a lower number of cells compared with
control shRNA, a defect that was not observed in the context of
PLC2 deletion. To confirm these findings, we performed an
MTTassay to compare the number of uninfected cells (ctrl) and
PLC1-deficient cells cultured in CSF-1-containing medium
for 6 days. We found a significant decrease in the number of
viable cells in the absence of PLC1 (Fig. 1D), suggesting that
the defect in OC differentiation might be due to reduced avail-
ability of OC precursors.
To clarify whether PLC1 deficiency inhibits osteoclast dif-
ferentiation via limiting cell number, we plated increasing
numbers of PLC1-deficient OC precursors in osteoclasto-
genic medium and analyzed their ability to undergo osteoclast
differentiation. Strikingly, the osteoclastogenesis defect was
rescued by plating higher numbers of shPLC1 cells (Fig. 1E).
Reduced cell number can be due to decreased cell prolifera-
tion or increased cell death (21). CSF-1 is well recognized to
activate key signaling pathways promoting OC precursor
FIGURE 1. PLC1 deficiency blocks osteoclastogenesis by limiting the
number of OC precursors. A, knockdown efficiency of five different shRNAs
targeting PLC1 inOCprecursorswas comparedwith ctrl and shctrl. Levels of
PLC2 and actin are used as loading controls. B, OC precursors infected with
the indicated shPLC1 constructs were cultured in osteoclastogenicmedium
for 5days. Representative images (top) andquantificationdata (bottom) show
that PLC1 deficiency leads to a severe osteoclastogenesis defect. C, infected
OC precursors were subjected toWestern blotting analysis for NFATc1, c-Src,
c-Fos, and PLC1. D, infected OC precursors cultured in CSF-1-containing
medium for 6 days were subjected to MTT assay to quantify the number of
cells available. E, increasing numbers of shPLC1-3- and shPLC1-4-infected
OC precursors were plated in osteoclastogenic medium, and OCs were enu-
merated after TRAP staining (OC quantification and representative images of
TRAP-stainedwells are shown).When indicated, error bars represent S.D., and
asterisks represent p 0.01 (**) and p 0.001 (***).
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proliferation and survival (22). In previous studies, we doc-
umented that high doses of CSF-1 could rescue the oste-
oclastogenic defect of cells lacking the v3 integrin (23) or
the co-stimulatory molecule DAP12 (24). However, high
concentrations of CSF-1 were not sufficient to rescue cell
numbers in PLC1-deficient cultures (Fig. 2A), thus suggest-
ing that PLC1 is a major downstream effector of CSF-1
signaling in OC precursors.
To understand whether PLC1 deficiency induces apoptosis
or affects cell proliferation, we examined cell death and BrdU
incorporation by ELISA. As shown in Fig. 2B, no significant
differences in cell death were observed between scrambled
shRNA (shctrl) and shPLC1 OC precursors cultured in CSF-
1-containing medium for 2, 4, or 6 days (Fig. 2B). By contrast,
the BrdU signal was lower in shPLC1 cells (Fig. 2C) in the
presence of both 30 and 100 ng/ml CSF-1. Confirming these
findings, cell cycle analysis revealed that shPLC1 cells were
arrested in G1 phase with fewer cells entering the S phase fol-
lowing 24-h exposure to CSF-1 (Fig. 2D).
It is established that CSF-1 activates PI3K/AKT and Grb2/
ERK pathways in OC precursors (22, 25). Therefore, we
hypothesized that PLC1modulates either AKT or ERK signal-
ing cascades to promote cell proliferation. In contrast to our
expectations, neither AKT nor ERK phosphorylation was
altered by PLC1 deficiency in response to CSF-1 (Fig. 3A).
CyclinD1, cyclinD2, and cyclinD3 are required for cell cycle
G1/S transition, and their expression is increased upon
CSF-1 stimulation (26). Interestingly, the levels of cyclinD1
were decreased in PLC1-deficient cells exposed to CSF-1 (Fig.
3B). We observed a similar result for cyclinD3 (not shown).
CyclinD1 is a downstream target of -catenin (27). -
Catenin has also been reported to participate in CSF-1-induced
OCprecursorproliferationviaamechanismthat is independentof
ERK/AKT phosphorylation (28, 29). Therefore, we wondered
whether PLC1 controls -catenin levels in OC precursors. Con-
sistent with cyclinD1 expression, -catenin levels were signifi-
cantly reduced in cells lackingPLC1 (Fig. 3,C andD). The reduc-
tion in -catenin was already observed in basal conditions and
becamemorepronouncedafter shortor longerexposure toCSF-1.
To clarify whether PLC1mediates CSF-1-induced cyclinD1
expression via regulation of -catenin, we used OC precursors
from mice expressing a non-degradable form of -catenin
driven by the lysozyme M (Lyz2; herein indicated as LysM)
promoter (LysM-Cre/Ctnnb1WT/floxEx3; herein referred to as
-catenin-CA) (30). To avoid confounding variables due to
activity of LysM-Cre in various myeloid populations, we iso-
lated -catenin-CA OC precursors and infected them ex vivo
with PLC1 or ctrl shRNAs to measure cyclinD1 levels follow-
FIGURE 2. PLC1 deficiency impairs CSF-1-induced proliferation. A, shctrl-, shPLC1-3-, and shPLC1-4-infected OC precursors were cultured in medium
containing the indicated concentrations of CSF-1 for 6 days, and cell number was assessed by MTT assay. B, shctrl- and shPLC1-infected OC precursors were
cultured in the presence of 100 ng/ml CSF-1 for the indicated days, and cell death was assessed by ELISA. C, shctrl- and shPLC1-infected OC precursors
were cultured in the presence of CSF-1 at the indicated concentrations for 3 days, and cells were then subjected to BrdU analysis. D, shctrl, shPLC1-3, and
shPLC1-4 cells were serum- and cytokine-starved for 24 h and then treated with 100 ng/ml CSF-1 for an additional 24 h before cell cycle analysis. When
indicated, error bars represent S.D., and asterisks represent p 0.05 (*), p 0.01 (**), and p 0.001 (***).
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ing 8-h exposure to CSF-1. As expected, cyclinD1 was down-
regulated in PLC1-deficient cells, whereas its levels were
increased in shPLC1/-catenin-CA cells (Fig. 4A). Consistent
with this result, cell number, assessed by MTT assay, was sig-
nificantly increased in shPLC1/-catenin-CA cultures versus
shPLC1 (Fig. 4B). To finally determine whether higher
-catenin levels could rescue shPLC1 defective osteoclasto-
genesis, shPLC1/-catenin-CA or shPLC1 cells were cul-
tured in osteoclastogenic medium for 7 days. Strikingly,
shPLC1/-catenin-CA cells formed significantlymoreOCs of
normal appearance than PLC1-deficient cells (Fig. 4C). Taken
together, these results suggest that PLC1 modulates the oste-
oclastogenic pathway via activation of the -catenin/cyclinD1
signaling cascade downstream of CSF-1.
PLC1 enzymatic activity leads to increased calcium levels
and DAG production (2). Because calcium is known to modu-
late NFATc1 and shPLC1 cells have normal NFATc1 levels,
we hypothesized that reducedDAGproductionmay be respon-
sible for impaired -catenin/cyclinD1 expression in PLC1-
deficient cells. To test this hypothesis, we turned to diacyl-
glycerol kinase  (DGK)-deficient OC precursors. DGK
modulates DAG levels in OC precursors by converting DAG
into phosphatidic acid, and thusDGK deficiency leads toDAG
accumulation (31, 32). We have recently documented that
DGK deficiency increases osteoclast numbers (32), leading to
the hypothesis that DAG accumulation could potentiate OC
precursor proliferation. Indeed, MTT (Fig. 5A) and BrdU (Fig.
5B) incorporation assays revealed higher numbers of DGK/
OC precursors compared with WT. This increase in cell num-
ber was observed in the presence of various concentrations of
CSF-1 (Fig. 5, A and B). In line with this result, -catenin and
cyclinD1 expression was significantly higher in DGK/ OC
precursors compared with WT cells (Fig. 5C).
To further determine whether impaired cyclinD1 expression
in PLC1-deficient OC precursors was due to decreased DAG
production, we compared cell proliferation in DGK/ and
DGK/ OC precursors infected with PLC1 shRNA con-
structs. As shown in Fig. 5D, shPLC1/DGK/ cultures
showed higher cell numbers when compared with shPLC1/
DGK/ cells. Consistently, the lower expression of cyclinD1
in shPLC1 cultures was rescued in shPLC1/DGK/ cells
(Fig. 5E). All together, these results demonstrate that PLC1
utilizes DAG signaling to promote OC precursor proliferation
in response to CSF-1.
Finally, to determine whether increased DAG levels could
rescue the OC differentiation defect observed in PLC1-defi-
cient cultures, we cultured shPLC1/DGK/OC precursors
in the presence of osteoclastogenic medium. Consistent with
our previous report (32), DGK/ OC precursors formed
more and larger osteoclasts than WT, whereas fewer and
smaller OCs were observed in the absence of PLC1 (Fig. 5F).
Notably, OC differentiation was normalized in shPLC1/
DGK/ OC cultures. Taken together, these results demon-
strate that CSF-1 activates the PLC1/DAG/-catenin/cy-
clinD1 pathway to support OC precursor proliferation, which
in turn benefits osteoclastogenesis.
We previously reported that PLC2 modulates OC differ-
entiation by regulating NFATc1 activation downstream of
RANKL signaling (12). PLC2 has also been implicated in cyto-
skeletal reorganization in response to CSF-1 stimulation and
FIGURE 3. PLC1 deficiency down-regulates -catenin and cyclinD1 lev-
els in response to CSF-1. A, shctrl- or shPLC1-infected OC precursors were
stimulated with 100 ng/ml CSF-1 for 0, 5, and 20 min and subjected to West-
ern blotting analysis for p-AKT andp-ERK. PYK2was used as loading control. B
and D, shctrl-, shPLC1-3-, and shPLC1-4-infected OC precursors were stim-
ulated with 100 ng/ml CSF-1 for 0, 8, and 16 h and blotted for cyclinD1,
-catenin, and CSF-1R. -Actin and PLC1 are used as controls. C, same cells
treated as in A blotted for -catenin and CSF-1R.
FIGURE 4. Defects caused by PLC1 deficiency can be rescued in
-catenin-CA cells. A, shctrl-, shPLC1-3-, and shPLC1-4-infected control
(Ctnnb1WT/WT; LysMcre/cre) and -catenin-CA (Ctnnb1WT/ex3flox; LysMcre/cre) OC
precursors were stimulated with 100 ng/ml CSF-1 for 8 h, and cyclinD1 levels
were analyzedbyWesternblotting.-Catenin,-actin, andPLC1 are used as
controls. B, shctrl- and shPLC1-infected controls and -catenin-CA OC pre-
cursors were plated at a concentration of 1 104/well and cultured in -10
medium containing 100 ng/ml CSF-1 for 8 days. Cell numberwas assessed by
MTT assay. C, shctrl- and shPLC1-infected controls and -catenin-CA OC
precursors were cultured in osteoclastogenic medium for 7 days, and differ-
entiated OCs were analyzed via TRAP staining. Representative images (left)
and quantification data (right) show that expression of -catenin-CA can
restore the osteoclastogenesis defect caused by PLC1 deficiency. When
indicated, error bars represent S.D., and asterisks represent p 0.001 (***).
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integrin engagement (33). Thus, we next asked whether PLC2
could also modulate CSF-1-dependent proliferative signals. To
this end, we compared cyclinD1 expression in WT and
PLC2/OC precursors exposed to CSF-1 and found no dif-
ferences (Fig. 6A). Consistent with this finding, no differences
were noted in the proliferation rate between WT and
PLC2/ cells (not shown). Furthermore, expression of
shPLC1 in WT, PLC2/, and PLC2/ cells leads to a
similar decrease in cell numbers, further suggesting that
PLC2 is not sufficient to compensate for the loss of PLC1
(Fig. 6B).
The different response between PLC1 and PLC2 to CSF-1
stimulation made us hypothesize that PLC1 is the main mod-
ulator of CSF-1 signals required forOCprecursor proliferation.
To elucidate this hypothesis, we examined whether CSF-1R
could associate with either PLC1 or PLC2. As shown in Fig.
6C, CSF-1R interacted with both PLC1 and PLC2 in basal
conditions. Interestingly, the association between PLC1 and
CSF-1R was further increased by CSF-1 stimulation, whereas
CSF-1R binding to PLC2 was decreased. Confirming activa-
tion of the receptor, we found a time-dependent increase in
CSF-1R tyrosine phosphorylation (Fig. 6C). In a reverse
immunoprecipitation assay using anti-PLC1 to pull down
the complex, we confirmed PLC1 binding to CSF-1R in
basal conditions and following CSF-1 stimulation (Fig. 6D).
By contrast, when we used anti-PLC2 to immunoprecipi-
tate the complex, we did not detect PLC2/CSF-1R binding
in response to CSF-1 stimulation (Fig. 6E). Taken together,
FIGURE 5.DAGaccumulationpromotes proliferation andnormalizes PLC1deficiency-inducedosteoclastogenesis defect.A, DGK/ or DGK/OC
precursors were treatedwith the indicated concentrations of CSF-1 for 6 days. Cell number was assessed byMTT assay. B, DGK/ or DGK/OC precursors
were cultured as in A for 3 days and then subjected to BrdU analysis. C, DGK/ or DGK/ OC precursors were stimulated with 100 ng/ml CSF-1 for 0, 4, 8,
and16hand subjected toWesternblottinganalysis for-catenin, cyclinD1,DGK, and-actin.D, DGK/orDGK/OCprecursorswere infectedwith shctrl,
shPLC1-3, and shPLC1-4; cultured in the presence of 100 ng/ml of CSF-1 for 6 days; and subjected toMTT assay. E, DGK/ or DGK/OCprecursors were
infected with shctrl, shPLC1-3, and shPLC1-4 and exposed to 100 ng/ml CSF-1 stimulation for 8 h. The samples were subjected toWestern blotting analysis
for cyclinD1, PLC1, DGK, and -actin. F, DGK/ or DGK/ OC precursors infected with shctrl, shPLC1-3, and shPLC1-4 were cultured in osteoclasto-
genic medium for 5 days followed by TRAP staining. Representative TRAP images (left) and quantification of number of mature OCs/well (right) are shown.
When indicated, error bars represent S.D., and asterisks represent p 0.05 (*), p 0.01 (**), and p 0.001 (***).
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these results demonstrate that CSF-1R recruits PLC1 but
not PLC2 in response to CSF-1 stimulation, and this could
explain why PLC1 but not PLC2 modulates CSF-1-in-
duced OC precursor proliferation.
Discussion
PLC1 and PLC2 are two highly homologous enzymes with
cell-specific, non-redundant biological functions (5). Although
both enzymes can be expressed in the same cell, often one
appears to play a dominant role over the other. Various hypoth-
eses have been proposed for the non-overlapping effects of
these two enzymes, ranging from different levels of expression
or inability to be recruited to the samemolecular complexes (3,
5). Interestingly, in the osteoclasts, both PLC1 and PLC2 are
required for osteoclastogenesis but do not compensate for each
other. Although our previouswork demonstrated that PLC2 is
activated downstreamof RANKand regulates expression ofOC
markers, we now find that PLC1 is activated in response to
CSF-1 and modulates OC precursor proliferation. To our
knowledge, this is the first known cell type where deletion of
either enzyme has major consequences on the cell differentia-
tion by acting on two different signaling pathways.
CSF-1 is an important cytokinemodulating critical pathways
required for OC precursor proliferation, survival, and cytoskel-
etal reorganization (17, 34), and mice lacking CSF-1 develop
osteopetrosis due to lack of osteoclasts (35). The two major
signaling pathways activated byCSF-1 are ERKandAKT,which
control cell proliferation and survival via the activation and
stabilization of D-type cyclins. Intriguingly, however, although
PLC1 deficiency suppresses OC precursor proliferation, it
does not alter CSF-1-induced ERKorAKTphosphorylation. By
contrast, PLC1 modulates cyclinD1 expression, a protein
known to modulate cell proliferation downstream of -catenin
(36). Although the role of -catenin in cell proliferation is well
established (28, 37), contradiction exists regarding the role of
-catenin in regulating osteoclast differentiation. In vitro
studies with cells from -catenin conditional knock-out or
-catenin constitutively active mice using peroxisome prolif-
erator-activated receptor  promoter driven Cre expression
show defective OC differentiation (29). By contrast, deletion of
-catenin using LysM promoter-driven Cre expression led to
osteopenia due to increased number ofOCs (38, 39). These data
suggest that balanced-catenin signals in osteoclast precursors
may be required for proper osteoclastogenesis. In addition,
treatment withWnt3a, which induces-catenin accumulation,
did not affect RANKL-induced osteoclastogenesis (40–42),
further implicating that how -catenin is activated might also
FIGURE 6. PLC1 but not PLC2 is recruited to CSF-1R after CSF-1 stimulation. A, WT and PLC2/OC precursors were stimulated with 100 ng/ml CSF-1
for 0, 8, and 16 h and subjected to Western blotting analysis for cyclinD1, PLC2, and -actin. B, PLC2/, PLC2/, and PLC2/ OC precursors were
infected with shctrl and shPLC1; cultured in the presence of 100 ng/ml CSF-1 for 6 days; and subjected toMTT assay. C–E, WT OC precursors were stimulated
with 100 ng/ml CSF-1 for 0, 0.5, 1, and 1.5 h; lysed; and subjected to immunoprecipitation (IP) using the following antibodies CSF-1R (C), PLC1 (D), and PLC2
(E) followed by Western blotting for the indicated proteins. When indicated, error bars represent S.D., and asterisks represent p 0.001 (***).
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play a critical role in the OC differentiation process. We show
that expression of -catenin-CA in cells lacking PLC1 is suf-
ficient to rescue cyclinD1 levels and cell proliferation, which in
turn normalizes the number of mature OCs. Our finding places
-catenin downstream of CSF-1/PLC1 signaling and is con-
sistent with the role of the DAP12/-catenin axis in promoting
macrophage proliferation independently of AKT/ERK activa-
tion (28).
PLC1 is known for converting PIP2 to IP3 and DAG (2, 4).
DAG is a secondmessenger that transduces signals modulating
a variety of cellular functions, including proliferation, motility,
and angiogenesis to name a few. We now demonstrate that
DAG production is required for PLC1 effects on macrophage
proliferation. BecauseDAG is unstable and deletion of a second
messenger cannot be achieved, we decided to useDGK knock-
out mice, which lack the kinase converting DAG into phospha-
tidic acid. We previously reported that DGK knock-out mice
exhibit lower bonemass and enhanced osteoclastogenesis com-
pared with WT mice (32); however, little is known about the
role of DAG in OC precursor proliferation. We now find that
DGK-deficient OC precursors have an increased proliferation
rate and higher cyclinD1 levels compared withWTmice. Most
importantly, deletion of theDGK in PLC1-deficient cells res-
cues CSF-1-induced proliferation and osteoclastogenesis.
Interestingly, we recently reported that DAG accumulation in
DGK-null OC precursors leads to higher c-Fos expression
(32), a mechanism conferring augmented osteoclast numbers.
However, c-Fos levels appear to be normal in PLC1-deficient
OC cultures. This result would suggest that DAG controls OC
formation by modulating c-Fos expression and affects OC pre-
cursor proliferation via the -catenin/cyclinD1 axis.
In conclusion, this study demonstrates that PLC1 works as
a novel and critical signal for the promotion of OC precursor
proliferation and thus osteoclastogenesis downstream of
CSF-1. PLC1 effects on the OCs are different compared with
PLC2,which is activated in response toRANKL.Clarifying the
exact roles of PLC1 and PLC2 in the regulation of osteoclas-
togenesis has important implications that go beyond their
effects on theOCs but also demonstrate how two highly homo-
logous molecules can specifically activate distinct pathways in
the same cell type.
Experimental Procedures
Primary Cell Cultures and Mice—OC precursors were iso-
lated and cultured as described previously (43). Briefly, bone
marrowwas harvested from femora and tibiae of 6–8-week-old
C57/BL6 mice. Cells were then cultured in -minimum essen-
tial medium (M0894, Sigma) containing 10% heat-inactivated
fetal bovine serum (26140, Gibco), 100 IU/ml penicillin plus
100 g/ml streptomycin (15140, Gibco), 2 mM glutamine (25-
005-Cl, Corning) (referred to as -10 medium), and 10% CMG
14-12 cell-conditioned medium (44) containing the equivalent
of 100 ng/ml CSF-1 for 3 days in Petri dishes. The attached cells
represent OC precursors ready to use. In some experiments,
purified CSF-1 (576404, Biolegend, San Diego, CA) was used to
stimulate OC precursors. To generate mature osteoclasts, OC
precursors were plated in a 96-well plate at a concentration of
5 103 cells/well in the presence of 100 ng/ml RANKL and 1%
CMG14-12 (containing the equivalent of 10 ng/ml CSF-1) for 6
days changing medium every day. The differentiated cells were
then fixed in 4% paraformaldehyde and subjected to TRAP
staining using a commercial kit (387A, Sigma). All experiments
were approved by the Washington University School of
Medicine animal care and use committee. Male and female
WT, DGK/, LysM-Cre/Ctnnb1WT/WT and LysM-Cre/
Ctnnb1WT/floxEx3 mice (C57BL/6 background), 6–8 weeks of
age, were used in the study. Mice were housed in cages and fed
with food and water ad libitum with a 12-h light and 12-h dark
cycle.
Lentivirus Generation and Infection—HEK293T cells were
cultured in Dulbecco’s modified Eagle’s medium containing
10% heat-inactivated fetal bovine serum, 100 IU/ml penicillin
plus 100 g/ml streptomycin, and 1 mM sodium pyruvate (25-
000-Cl, Corning). Five PLC1 lentiviral shRNAs constructs in
PLKO.1 vector containing a puromycin resistance cassette
were purchased from Washington University RNAi core (St.
Louis,MO). shPLC1-1 (targeting GCCAGCTTGTAGCACT-
CAATT), shPLC1-2 (targeting CCCGTGAATCATGAGTG-
GTAT), shPLC1-3 (targeting CCAACTTTCAAGTGTGCA-
GTA), shPLC1-4 (targeting CCAGATCAGTAACCCA-
GAGTT), shPLC1-5 (targeting GCCAGATCAATCACACT-
GCTT), and shctrl were co-transfected with a packaging plas-
mid (Delta8.2) and envelope plasmid (VSVg) into HEK293T
cells using Polyjet transfection reagent (SL100688, SignaGen
Laboratories, Gaithersburg, MD). Supernatants containing the
lentivirus were harvested 36–48 h after transfection, filtered,
and used to infect OC precursors. 50% lentivirus supernatant
and 10% CMG 14-12 in -10 medium with additional 8 g/ml
Polybrene were added to the cells for 24 h. Cells were then
selected in -10 medium containing 10% CMG 14-12 and 2
g/ml puromycin for 24 h prior to being used for the indicated
experiments.
MTT Assay—shPLC1 or shctrl OC precursors were plated
in a 96-well plate at a concentration of 2.5 103 cells/well and
cultured for few days in -10 medium containing either 10%
CMG 14-12 or purified CSF-1 at the indicated concentrations.
Cells were then incubated with 0.5 mg/ml MTT (M2128,
Sigma) for 2.5 h. The crystalline formation was dissolved in 150
l of DMSO (D5879, Sigma) followed by a spectrophotometric
reading at A540 (EL-800, Bio-Tek, Winooski, VT).
BrdUAssay—TheBrdUassaywas performedusing a cell pro-
liferation ELISA kit (11647229001, Roche Applied Science).
shctrl- and shPLC1-infected cells or WT (DGK/) and
DGK/OCprecursors were plated in 96-well plates at a con-
centration of 5  103/well and cultured in -10 medium con-
taining purified CSF-1 at the indicated concentrations for 3
days. Cells were then incubated with 0.1% BrdU for 4 h at 37 °C,
fixed for 30 min at room temperature, and incubated with
blocking reagent for another 30 min. Peroxidase-labeled anti-
BrdU antibody was then added for 90min, and BrdU signal was
measured at A450 following reaction with the appropriate sub-
strate as indicated in the manufacturer’s instructions.
Cell Death ELISA—Cell death was examined by using a com-
mercial kit (11774425001, RocheApplied Science). Briefly, shc-
trl- and shPLC1-infected OC precursors were cultured in
-10 medium containing 10% CMG 14-12 for 2, 4, or 6 days.
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Cells were then resuspended in 200 l of lysis buffer and incu-
bated for 30 min, and lysates were centrifuged at 200 g for 10
min. 20 l of supernatant was transferred into a streptavidin-
coated microplate strip with an additional 80 l of immunore-
agent (72 l of incubation buffer, 4 l of anti-histone-biotin,
and 4 l of anti-DNA-peroxidase). The mixture was then incu-
bated on a microplate shaker under gentle shaking (300 rpm)
for 2 h. After washing with incubation buffer, the immunocom-
plex was incubated with 100 l of 2,2-azinobis(3-ethylbenzo-
thiazoline-6-sulfonic acid solution for 20 min, and the reaction
was stopped by adding 100 l of 2,2-azinobis(3-ethylbenzo-
thiazoline-6-sulfonic acid stop solution. A405 and A490 (refer-
ence) were recorded, and cell death was assessed by calculating
(A405 A490).
Cell Cycle Analysis—3  105 shctrl-, shPLC1-3-, and
shPLC1-4-infected cells were seeded into 6-cm Petri dishes in
-10medium containing 10%CMG 14-12. Cells were synchro-
nized by 24-h starvation, stimulated with 100 ng/ml purified
CSF-1 for 24 h, and fixed in 70% ethanol at 20 °C overnight.
Samples were stained with 100 g/ml propidium iodide
(R4170, Sigma) in the presence of 100 g/ml RNase (R6513,
Sigma) for 30 min at 37 °C and analyzed by flow cytometry (BD
FACSCalibur, BD Biosciences). Results were assessed using
FlowJo software (Treestar, Inc., San Carlos, CA).
Western Blotting—For -catenin/cyclinD1 analysis and
AKT/ERK signaling, 2  105 OC precursors were plated in
6-well plates in the presence of -10 medium containing 10%
CMG 14-12. Adherent cells were then starved from serum and
cytokines for 24 h followed by stimulation with 100 ng/ml
CSF-1 for indicated time. Cells were directly lysed in 1 SDS
loading buffer and subjected to Western blotting analysis. The
following antibodies were used: cyclinD1 (2978, Cell Signaling
Technology, Danvers, MA; 1:1000), -catenin (9587, Cell Sig-
naling Technology; 1:1000), PLC1 (2822, Cell Signaling Tech-
nology; 1:1000), PLC2 (3872, Cell Signaling Technology;
1:1000), DGK (sc-8722, Santa Cruz Biotechnology; 1:500),
-actin (A5441, Sigma; 1:5000), p-AKT (9271, Cell Signaling
Technology; 1:1000), p-ERK (4377, Cell Signaling Technology;
1:1000), and PYK2 (3292, Cell Signaling Technology; 1:1000).
For Western Blotting analysis in mature osteoclasts, 3  104
infected OC precursors were plated in 12-well plates in oste-
oclastogenic medium for 5 days, and the medium was changed
every day. The differentiated cells were lysed in TNE buffer (10
mM Tris, pH 7.4, 150 mMNaCl, 1% Nonidet P-40, 1 mM EDTA,
10% (v/v) glycerol) and subjected to Western blotting using
specific antibodies for NFATc1 (sc-7294, Santa Cruz Biotech-
nology; 1:500), c-Src (sc-18, Santa Cruz Biotechnology; 1:500),
c-Fos (2250, Cell Signaling Technology; 1:1000), PLC1
(1:1000), and -actin (1:5000).
Co-immunoprecipitation—OC precursors were cultured in
10-cm Petri dishes until confluence, and cells were starved
overnight in serum- and cytokine-free medium. Starved cells
were then stimulated with 100 ng/ml CSF-1 for 0.5, 1, and 1.5 h
after which they were lysed in TNE buffer containing protease
inhibitors (78442, Thermo Fisher, Rockford, IL). 250-g pro-
tein samples were incubated with 1 g of anti-CSF-1R (sc-692,
Santa Cruz Biotechnology), anti-PLC1 or anti-PLC2 anti-
body at 4 °Covernight followedby proteinA/Gbead incubation
at 4 °C for an additional 3 h. The immunocomplex was washed
with PBS three times and subjected to Western blotting using
specific antibodies for PLC1 (1:1000), PLC2 (1:1000), 4G10
(05-321, Upstate Biotechnology, Lake Placid, NY; 1:2000), and
CSF-1R (1:500).
Statistical Analysis—Data are represented asmean S.D. for
absolute values as indicated in the vertical axis of the figures.
Two-tailed one-type Student’s t test was performed to analyze p
values between experimental and control groups. All experi-
ments with multiple parameters (groups, days, or concentra-
tions) were analyzed by using a two-way analysis of variance
followed by Bonferroni post-tests. p  0.05 was considered to
be statistically significant. *, p 0.05; **, p 0.01; ***, p 0.001.
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